RESUMO
The generation of insulin-producing cells (IPCs) is an attractive approach for replacing damaged ß cells in diabetic patients. In the present work, we introduced a hybrid platform of decellularized amniotic membrane (dAM) and fibrin encapsulation for differentiating adipose tissue-derived stem cells (ASCs) into IPCs. ASCs were isolated from healthy donors and characterized. Human AM was decellularized, and its morphology, DNA, collagen, glycosaminoglycan (GAG) contents, and biocompatibility were evaluated. ASCs were subjected to four IPC differentiation methods, and the most efficient method was selected for the experiment. ASCs were seeded onto dAM, alone or encapsulated in fibrin gel with various thrombin concentrations, and differentiated into IPCs according to a method applying serum-free media containing 2-mercaptoethanol, nicotinamide, and exendin-4. PDX-1, GLUT-2 and insulin expression were evaluated in differentiated cells using real-time PCR. Structural integrity and collagen and GAG contents of AM were preserved after decellularization, while DNA content was minimized. Cultivating ASCs on dAM augmented their attachment, proliferation, and viability and enhanced the expression of PDX-1, GLUT-2, and insulin in differentiated cells. Encapsulating ASCs in fibrin gel containing 2 mg/ml fibrinogen and 10 units/ml thrombin increased their differentiation into IPCs. dAM and fibrin gel synergistically enhanced the differentiation of ASCs into IPCs, which could be considered an appropriate strategy for replacing damaged ß cells.
Assuntos
Tecido Adiposo , Diferenciação Celular , Fibrina , Insulina , Células-Tronco , Humanos , Diferenciação Celular/efeitos dos fármacos , Fibrina/química , Fibrina/metabolismo , Tecido Adiposo/citologia , Tecido Adiposo/metabolismo , Células-Tronco/metabolismo , Células-Tronco/citologia , Insulina/metabolismo , Células Cultivadas , Células Secretoras de Insulina/metabolismo , Células Secretoras de Insulina/citologia , Matriz Extracelular Descelularizada/química , Matriz Extracelular Descelularizada/metabolismo , Matriz Extracelular Descelularizada/farmacologia , Âmnio/citologia , Âmnio/metabolismo , Âmnio/químicaRESUMO
The clinical importance of viscoelastic testing in patient blood management when performing cardiovascular surgery is increasing. We aimed to examine the effect of a blood transfusion protocol including an assessment of fibrin-based rotational thromboelastometry on transfusion volume, mortality, and bleeding complications in patients undergoing cardiac or thoracic aortic surgery. We retrospectively studied a cohort of 376 consecutive patients who underwent cardiopulmonary bypass before (control group: 150 cardiac and 35 thoracic aortic surgeries) and after (assessment group: 154 cardiac and 37 thoracic aortic surgeries) introducing the fibrin polymerization assessment with thromboelastometry in the blood transfusion protocol. The transfusion volume and clinical outcomes were compared between the control and assessment groups, and the standardized (mean) difference (S[M]D) was calculated as an indicator of statistical effect size. Compared with the control group, the assessment group had a lower total blood transfusion volume (mL) in cardiac (2720 ± 1282 vs. 2034 ± 1330, p < 0.0001, [SMD] = 0.68) and thoracic aortic surgeries (5236 ± 2732 vs. 3714 ± 1768, p < 0.0001, SMD = 0.67). The 1-year mortality rates were 1.9 % and 2.7 % in cardiac and thoracic aortic surgeries, respectively. Significant differences were not observed in the 1-year mortality (3.2 % vs. 1.0 %, p = 0.16, relative risk [RR] = 0.32 with 95 % confidence intervals [CI] = 0.06-1.57, SD = 0.15), re-exploration for bleeding (4.8 % vs. 2.6 %, p = 0.28, RR = 0.53 with 95 % CI = 0.18-1.57, SD = 0.12), and major bleeding (17.3 % vs. 13.0 %, p = 0.31, RR = 0.75 with 95 % CI = 0.46-1.22, SD = 0.12) rates between the control and assessment groups. The assessment of fibrin polymerization with thromboelastometry using the blood transfusion protocol reduced the blood transfusion volume in cardiovascular surgery.
Assuntos
Transfusão de Sangue/métodos , Procedimentos Cirúrgicos Cardíacos/métodos , Fibrina/metabolismo , Tromboelastografia/métodos , Idoso , Estudos de Coortes , Feminino , Humanos , Masculino , Resultado do TratamentoRESUMO
Diseases such as myocardial infarction, ischaemic stroke, peripheral vascular disease and venous thromboembolism are major contributors to morbidity and mortality. Procoagulant, anticoagulant and fibrinolytic pathways are finely regulated in healthy individuals and dysregulated procoagulant, anticoagulant and fibrinolytic pathways lead to arterial and venous thrombosis. In this review article, we discuss the (patho)physiological role and laboratory assessment of fibrin, factor XIII and endogenous fibrinolysis, which are key players in the terminal phase of the coagulation cascade and fibrinolysis. Finally, we present the most up-to-date evidence for their involvement in various disease states and assessment of cardiovascular risk.
Assuntos
Fator XIII/fisiologia , Fibrina/fisiologia , Trombose/fisiopatologia , Fator XIII/análise , Fator XIII/metabolismo , Fibrina/análise , Fibrina/metabolismo , Fibrinólise , Humanos , Trombose/sangue , Trombose/metabolismo , Trombose Venosa/sangue , Trombose Venosa/metabolismo , Trombose Venosa/fisiopatologiaRESUMO
BACKGROUND: Thrombelastometry, allowing timely assessment of global hemostatic function, is increasingly used to guide hemostatic interventions in bleeding patients. Reference values are available for adults and children, including infants but not neonates immediately after birth. METHODS: Neonates were grouped as preterm (30 + 0 to 36 + 6 weeks/days) and term (37 + 0 to 39 + 6 weeks/days). Blood samples were drawn from the umbilical cord immediately after cesarean section and analyzed by thrombelastometry. Reference ranges were determined for the extrinsic and intrinsic coagulation pathways, fibrin polymerization, and hyperfibrinolysis detection. RESULTS: All extrinsically activated test parameters, but maximum lysis (P = 0.139) differed significantly between both groups (P ≤ 0.001). Maximum clot firmness in the fibrin polymerization test was comparable (P = 0.141). All intrinsically activated test parameters other than coagulation time (P = 0.537) and maximum lysis (P = 0.888) differed significantly (P < 0.001), and so did all aprotinin-related test parameters (P ≤ 0.001) but maximum lysis (P = 0.851). CONCLUSIONS: This is the first study to identify reference ranges for thrombelastometry in preterm and term neonates immediately after birth. We also report differences in clot initiation and clot strength in neonates born <37 versus ≤40 weeks of gestation, mirroring developmental hemostasis. IMPACT: Impact: This prospective observational study is the first to present reference ranges in preterm and term infants for all types of commercially available tests of thrombelastometry, notably also including the fibrin polymerization test. IMPORTANCE: Viscoelastic coagulation assays such as thrombelastometry have become integral to the management of perioperative bleeding by present-day standards. Reference values are available for adults, children, and infants but not for neonates. Key message: Clot initiation and formation was faster and clot strength higher in the term than in the preterm group. Parameters of thrombelastometry obtained from cord blood do not apply interchangeably to preterm and term neonates.
Assuntos
Coagulação Sanguínea , Sangue Fetal/metabolismo , Fibrina/metabolismo , Recém-Nascido Prematuro/sangue , Testes Imediatos/normas , Nascimento a Termo/sangue , Tromboelastografia/normas , Biomarcadores/sangue , Feminino , Idade Gestacional , Humanos , Recém-Nascido , Masculino , Valor Preditivo dos Testes , Estudos Prospectivos , Valores de ReferênciaRESUMO
Nanoparticles (NPs) are promising products in industry and medicine due to their unique physicochemical properties. In particular, zinc oxide (ZnO) NPs are extensively incorporated into sunscreens to protect the skin from exposure to ultraviolet radiation. However, there are several health concerns about skin penetration and the resultant toxicity. As methodologies for evaluating NP toxicity are under development, it is difficult to fully assess the toxicity of ZnO NPs toward humans. In this study, we developed a platform to simultaneously detect skin permeability to and pro-inflammatory activity mediated by zinc ion released from NPs. First, we generated a stable reporter cell line expressing green fluorescent protein (GFP) under the control of interleukin-8 (IL-8) promoter activity. The expression levels of GFP induced by zinc reflected the endogenous IL-8 expression levels and the pro-inflammatory responses. Next, we found that fibrin hydrogel can reproduce permeability to zinc ion of a human skin equivalent model and is therefore a promising material to assess skin permeability to zinc ion. Then, we constructed a fibrin hydrogel-based in vitro bioassay system for the simultaneous detection of skin permeability to and pro-inflammatory activity mediated by zinc ion released from NPs by using a stable reporter cell line and a fibrin hydrogel layer. This bioassay system is a promising in vitro permeation test due to its technical simplicity and good predictability. Overall, we believe that our bioassay system can be widely used in the cosmetics and pharmaceutical industries.
Assuntos
Bioensaio/métodos , Fibrina/química , Hidrogéis/química , Inflamação/metabolismo , Nanopartículas Metálicas/química , Pele/efeitos dos fármacos , Zinco/farmacologia , Alginatos/metabolismo , Linhagem Celular , Colágeno/metabolismo , Fibrina/metabolismo , Humanos , Técnicas In Vitro , Interleucina-8/genética , Interleucina-8/metabolismo , Permeabilidade , Pele/metabolismo , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Accurate assessment of blood thrombosis and antithrombotic therapy is essential for the management of patients in a variety of clinical conditions, including surgery and on extracorporeal life support. However, current monitoring devices do not measure the effects of hemodynamic forces that contribute significantly to coagulation, platelet function and fibrin formation. This limits the extent to which current assays can predict clotting status in patients. Here, we demonstrate that a biomimetic microfluidic device consisting stenosed and tortuous arteriolar vessels would analyze blood clotting under flow, while requiring a small blood volume. When the device is connected to an inline pressure sensor a clotting time analysis is applied, allowing for the accurate measurement of coagulation, platelets and fibrin content. Furthermore, this device detects a prolonged clotting time in clinical blood samples drawn from pediatric patients on extracorporeal membrane oxygenation receiving anticoagulant therapy. Thus, this tortuosity activated microfluidic device could lead to a more quantitative and rapid assessment of clotting disorders and their treatment.
Assuntos
Anticoagulantes/farmacologia , Testes de Coagulação Sanguínea/instrumentação , Fibrinolíticos/farmacologia , Dispositivos Lab-On-A-Chip , Trombose/sangue , Anticoagulantes/uso terapêutico , Coagulação Sanguínea/efeitos dos fármacos , Plaquetas/citologia , Plaquetas/efeitos dos fármacos , Criança , Pré-Escolar , Monitoramento de Medicamentos/instrumentação , Desenho de Equipamento , Oxigenação por Membrana Extracorpórea , Fibrina/metabolismo , Fibrinolíticos/uso terapêutico , Humanos , Trombose/tratamento farmacológico , Trombose/metabolismoRESUMO
BACKGROUND AND AIMS: Crohn's disease (CD) is a chronic inflammatory condition characterized by continuous mucosal damage and ongoing wound healing of the intestines. The fibrinolytic system is involved in early parts of the wound healing process. Fibrin is a key mediator of primary blood clot formation and is formed by cross-linking of fibrinogen. To gain insights into the dynamics of wound healing in CD patients we investigated the conversion of fibrinogen into fibrin by the pro-peptide FPA, the amount of factor XIII cross-linked fibrin and total fibrin clot. METHODS: Serum samples of 35 CD patients, 15 non-inflammatory bowel disease (non-IBD) patients and 39 age-matched healthy controls were analyzed for three novel neo-epitope markers: D-fragment and D-dimer, reflecting the degradation of total fibrin clot and factor XIII cross-linked fibrin, as well as FPA, reflecting synthesis of fibrin. RESULTS: Crohn's disease patients had a significantly lower D-dimer level (p=0.0001) compared to healthy controls. Crohn's disease and non-IBD patients had a significantly higher level of FPA (p<0.0001) and D-fragment/D-dimer ratio (p<0.0001 and p=0.02). FPA, D-dimer and D-fragment/D-dimer ratio could distinguish CD patients from healthy controls with area under the curve of 0.92 (95% CI 0.83-0.97), 0.78 (95% CI 0.67-0.87) and 0.85 (95% CI 0.75-0.93), respectively. CONCLUSION: Wound healing parameters were clearly changed in CD patients. FPA levels were higher in CD patients as compared to healthy controls, indicating more ongoing wound healing. D-dimer levels were lower in CD patients than in healthy controls, indicating impaired wound healing due to poor quality of factor XIII cross-linked fibrin and clot resolution.
Assuntos
Doença de Crohn/fisiopatologia , Fibrina/metabolismo , Fibrinogênio/metabolismo , Cicatrização/fisiologia , Adulto , Idoso , Biomarcadores/sangue , Estudos de Casos e Controles , Doença de Crohn/sangue , Doença de Crohn/diagnóstico , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Fibrinopeptídeo A/metabolismo , Humanos , Mucosa Intestinal/fisiologia , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de DoençaRESUMO
Adhesion of Staphylococcus aureus to endothelial cells (ECs) is paramount in infective endocarditis. Bacterial proteins such as clumping factor A (ClfA) and fibronectin binding protein A (FnbpA) mediate adhesion to EC surface molecules and (sub)endothelial matrix proteins including fibrinogen (Fg), fibrin, fibronectin (Fn) and von Willebrand factor (vWF). We studied the influence of shear flow and plasma on the binding of ClfA and FnbpA (including its sub-domains A, A16+, ABC, CD) to coverslip-coated vWF, Fg/fibrin, Fn or confluent ECs, making use of Lactococcus lactis, expressing these adhesins heterologously. Global adherence profiles were similar in static and flow conditions. In the absence of plasma, L. lactis-clfA binding to Fg increased with shear forces, whereas binding to fibrin did not. The degree of adhesion of L. lactis-fnbpA to EC-bound Fn and of L. lactis-clfA to EC-bound Fg, furthermore, was similar to that of L. lactis-clfA to coated vWF domain A1, in the presence of vWF-binding protein (vWbp). Yet, in plasma, L. lactis-clfA adherence to activated EC-vWF/vWbp dropped over 10 minutes by 80% due to vWF-hydrolysis by a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 and that of L. lactis-fnbpA likewise by > 70% compared to the adhesion in absence of plasma. In contrast, plasma Fg supported high L. lactis-clfA binding to resting and activated ECs. Or, in plasma S. aureus adhesion to active endothelium occurs mainly via two complementary pathways: a rapid but short-lived vWF/vWbp pathway and a stable integrin-coupled Fg-pathway. Hence, the pharmacological inhibition of ClfA-Fg interactions may constitute a valuable additive treatment in infective endocarditis.
Assuntos
Proteína ADAMTS13/sangue , Aderência Bacteriana , Coagulase/metabolismo , Endocardite Bacteriana/microbiologia , Células Endoteliais da Veia Umbilical Humana/microbiologia , Plasma/enzimologia , Staphylococcus aureus/metabolismo , Adesinas Bacterianas/genética , Adesinas Bacterianas/metabolismo , Células Cultivadas , Coagulase/genética , Endocardite Bacteriana/sangue , Fibrina/metabolismo , Fibrinogênio , Fibronectinas/metabolismo , Células Endoteliais da Veia Umbilical Humana/metabolismo , Humanos , Lactococcus lactis/genética , Lactococcus lactis/metabolismo , Ligação Proteica , Domínios e Motivos de Interação entre Proteínas , Staphylococcus aureus/genética , Estresse Mecânico , Fator de von Willebrand/metabolismoRESUMO
In recent work, we discovered that the presence of highly substoichiometric amounts (10-8 molar ratio) of lipopolysaccharide (LPS) from Gram-negative bacteria caused fibrinogen clotting to lead to the formation of an amyloid form of fibrin. We here show that the broadly equivalent lipoteichoic acids (LTAs) from two species of Gram-positive bacteria have similarly (if not more) potent effects. Using thioflavin T fluorescence to detect amyloid as before, the addition of low concentrations of free ferric ion is found to have similar effects. Luminescent conjugated oligothiophene dyes (LCOs), marketed under the trade name Amytracker™, also stain classical amyloid structures. We here show that they too give very large fluorescence enhancements when clotting is initiated in the presence of the four amyloidogens (LPS, ferric ions and two LTA types). The staining patterns differ significantly as a function of both the amyloidogens and the dyes used to assess them, indicating clearly that the nature of the clots formed is different. This is also the case when clotting is measured viscometrically using thromboelastography. Overall, the data provide further evidence for an important role of bacterial cell wall products in the various coagulopathies that are observable in chronic, inflammatory diseases. The assays may have potential in both diagnostics and therapeutics.
Assuntos
Amiloide , Coagulação Sanguínea/efeitos dos fármacos , Fibrina , Corantes Fluorescentes , Bactérias Gram-Negativas/química , Lipopolissacarídeos , Ácidos Teicoicos , Amiloide/química , Amiloide/metabolismo , Feminino , Fibrina/química , Fibrina/metabolismo , Corantes Fluorescentes/química , Corantes Fluorescentes/farmacologia , Humanos , Lipopolissacarídeos/química , Lipopolissacarídeos/farmacologia , Masculino , Ácidos Teicoicos/química , Ácidos Teicoicos/farmacologiaAssuntos
Antitrombinas/administração & dosagem , Fibrina/metabolismo , Hirudinas/administração & dosagem , Complicações Intraoperatórias/tratamento farmacológico , Fragmentos de Peptídeos/administração & dosagem , Polimerização , Substituição da Valva Aórtica Transcateter/efeitos adversos , Idoso de 80 Anos ou mais , Estenose da Valva Aórtica/tratamento farmacológico , Estenose da Valva Aórtica/cirurgia , Humanos , Complicações Intraoperatórias/etiologia , Masculino , Proteínas Recombinantes/administração & dosagem , Tromboelastografia/métodos , Substituição da Valva Aórtica Transcateter/métodosRESUMO
The vascular endothelium and shear stress are critical determinants of physiological hemostasis and platelet function in vivo, yet current diagnostic and monitoring devices do not fully incorporate endothelial function under flow in their assessment and, therefore, they can be unreliable and inaccurate. It is challenging to include the endothelium in assays for clinical laboratories or point-of-care settings because living cell cultures are not sufficiently robust. Here, we describe a microfluidic device that is lined by a human endothelium that is chemically fixed, but still retains its ability to modulate hemostasis under continuous flow in vitro even after few days of storage. This device lined with a fixed endothelium supports formation of platelet-rich thrombi in the presence of physiological shear, similar to a living arterial vessel. We demonstrate the potential clinical value of this device by showing that thrombus formation and platelet function can be measured within minutes using a small volume (0.5 mL) of whole blood taken from subjects receiving antiplatelet medications. The inclusion of a fixed endothelial microvessel will lead to biomimetic analytical devices that can potentially be used for diagnostics and point-of-care applications.
Assuntos
Endotélio Vascular/efeitos dos fármacos , Dispositivos Lab-On-A-Chip , Trombose/diagnóstico , Plaquetas/efeitos dos fármacos , Células Endoteliais/efeitos dos fármacos , Fibrina/metabolismo , Células Endoteliais da Veia Umbilical Humana , Humanos , Inibidores da Agregação Plaquetária/farmacologia , Sistemas Automatizados de Assistência Junto ao Leito , Estresse Mecânico , Trombose/sangue , Trombose/tratamento farmacológicoRESUMO
BACKGROUND: Non-specific hemostatic agents, namely activated prothrombin complex concentrate (aPCC), PCC and recombinant activated factor (F) VII (rFVIIa), can be used, off-label, to reverse the effects of FXa inhibitors in the rare cases of severe hemorrhages, as no approved specific antidote is available. We have evaluated the ability of aPCC, PCC and rFVIIa to reverse apixaban. METHODS: Healthy volunteer whole blood was spiked with therapeutic or supra-therapeutic apixaban concentrations and two doses of aPCC, PCC or rFVIIa. Tests performed included a turbidimetry assay for fibrin polymerization kinetics analysis, scanning electron microscopy for fibrin network structure observation, thrombin generation assay (TGA), thromboelastometry, prothrombin time and activated partial thromboplastin time. RESULTS: aPCC generated a dense clot constituting thin and branched fibers similar to those of a control without apixaban, increased fibrin polymerization velocity and improved quantitative (endogenous thrombin potential and peak height) as well as latency (clotting and lag times) parameters. Adding PCC also improved the fibrin and increased quantitative parameters, but fibrin polymerization kinetics and latency parameters were not corrected. Finally, rFVIIa improved latency parameters but failed to restore the fibrin network structure, fibrin polymerization velocity and quantitative parameters. CONCLUSION: aPCC was more effective than PCC or rFVIIa in reversing in vitro the effects of apixaban. aPCC rapidly triggered the development of an apparently normal fibrin network and corrected latency and quantitative parameters, whereas PCC or rFVIIa had only a partial effect.
Assuntos
Inibidores do Fator Xa/farmacologia , Inibidores do Fator Xa/toxicidade , Hemorragia/prevenção & controle , Hemostasia/efeitos dos fármacos , Hemostáticos/farmacologia , Pirazóis/toxicidade , Piridonas/toxicidade , Antídotos/farmacologia , Coagulação Sanguínea/efeitos dos fármacos , Fatores de Coagulação Sanguínea/farmacologia , Fator VIIa/farmacologia , Fibrina/metabolismo , Fibrina/ultraestrutura , Voluntários Saudáveis , Hemorragia/sangue , Hemorragia/induzido quimicamente , Humanos , Cinética , Microscopia Eletrônica de Varredura , Tempo de Tromboplastina Parcial , Polimerização , Tempo de Protrombina , Proteínas Recombinantes/farmacologia , Tromboelastografia , Trombina/metabolismoRESUMO
The fibrin clot permeability coefficient (Ks) is a useful measure of porosity of the fibrin network, which is determined by a number of genetic and environmental factors. Currently available methods to evaluate Ks are time-consuming, require constant supervision and provide only one parameter. We present an automated method in which drops are weighed individually, buffer is dosed by the pump and well defined clot washing is controlled by the software. The presence of a straight association between drop mass and their dripping time allows to shorten the measurement time twice. In 40 healthy individuals, Ks, the number of drops required to reach the plateau (DTP), the time to achieve the plateau (TTP) and the DTP/TTP ratio (DTR) were calculated. There was a positive association between Ks (râ=â0.69, Pâ<â0.0001) evaluated by using the manual [median of 4.17 (3.60-5.18) ·10â»9âcm²) and the automated method [median of 4.35 (3.74-5.38) ·10â»9âcm²]. The correlation was stronger (râ=â0.85, Pâ<â0.001) in clots with DTP of 7 or less (nâ=â12). DTP was associated with total homocysteine (tHcy) (râ=â0.35, Pâ<â0.05) and activated partial thromboplastin time (APTT) (râ=â-0.34, Pâ<â0.05), TTP with Ks (râ=â-0.55, Pâ<â0.01 for the manual method and râ=â-0.44, Pâ<â0.01 for the automated method) and DTP (râ=â0.75, Pâ<â0.0001), and DTR with Ks (râ=â0.70, Pâ<â0.0001 for the manual method and râ=â0.76, Pâ<â0.0001 for the automated method), fibrinogen (râ=â-0.58, Pâ<â0.0001) and C-reactive protein (CRP) (râ=â-0.47, Pâ<â0.01). The automated method might be a suitable tool for research and clinical use and may offer more additional parameters describing fibrin clot structure.
Assuntos
Fibrina/análise , Testes Hematológicos/métodos , Adulto , Automação/métodos , Feminino , Fibrina/metabolismo , Fibrinogênio/metabolismo , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Permeabilidade , Adulto JovemRESUMO
OBJECTIVES: The purpose of this prospective study was to evaluate the utility of preferential application of pharmacoprophylaxis based on the quantitative evaluation by soluble fibrin (SF) and plasminogen activator inhibitor-1 (PAI-1) analysis on the day after total hip arthroplasty (THA). METHODS: A hundred and sixteen patients were enrolled. High-risk patients were defined as those with elevated levels of SF or PAI-1, beyond their cut-off values, on the day after THA. For high-risk patients, fondaparinux was administered for 10 days postoperatively. When both plasma levels of SF and PAI-1 were less than their cutoff levels, the patients were regarded to be at low risk. For low-risk patients, only mechanical prophylaxis was applied. RESULTS: Sixty patients (52%) were considered to be at high risk. Among them, venous thromboembolism (VTE) was detected in five patients (8%) by CT angiography. In addition, there were four patients (3%) who developed bleeding complications. Fifty-six patients (48%) were considered to be at low risk, and only one patient (2%) developed VTE. CONCLUSION: The measurement of SF and PAI-1 levels on the day after surgery may be helpful to identify the individual risk for postoperative VTE. According to this evaluation, a half of patients might not need to administer anticoagulant agents following surgery.
Assuntos
Anticoagulantes/uso terapêutico , Artroplastia de Quadril/efeitos adversos , Fibrina/metabolismo , Inibidor 1 de Ativador de Plasminogênio/sangue , Polissacarídeos/uso terapêutico , Tromboembolia Venosa/prevenção & controle , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Fondaparinux , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Medição de Risco , Resultado do Tratamento , Tromboembolia Venosa/etiologiaRESUMO
Using the E. coli, we fabricated the gene reconstructed brain derived neurotrophic factor with a fibrin binding domain (FBD-BDNF). We then tested the neurotrophic bioactivity and fibrin-binding ability of the FBD-BDNF. The E. coli was used to express the recombinant protein. The inclusion body was purified with column chromatography and renaturated to construct the right 3D formation. In this study, we successfully fabricated the FBD-BDNF and tested the binding ability and neurotrophic activity. The results demonstrated that FBD-BDNF had special binding ability of fibrin and significant neurotrophic activity for DRG cells. FBD-BDNF could have a promising application prospect in nerve tissue engineering.
Assuntos
Fator Neurotrófico Derivado do Encéfalo/biossíntese , Escherichia coli/metabolismo , Fibrina/metabolismo , Proteínas Recombinantes de Fusão/biossíntese , Fator Neurotrófico Derivado do Encéfalo/genética , Escherichia coli/genética , Vetores Genéticos/genética , Humanos , Ligação Proteica , Proteínas Recombinantes de Fusão/genéticaRESUMO
The advent of drug-eluting balloon (DEB) therapy has represented an important development in interventional cardiology. Nevertheless, preclinical data with this technology remain scant, and comparative studies have not previously been published. Bare metal stents were implanted in the coronary arteries of 15 pigs followed by balloon angioplasty. Animals were allocated to treatment with a 60-second inflation of one of four different balloon catheters: a conventional untreated plain angioplasty balloon (PBA, Biotronik AG), the Pantera Lux DEB (3.0 µg/mm2 paclitaxel; BTHC excipient, Biotronik AG), the Elutax DEB (2.0 µg/mm2 paclitaxel; no excipient; Aachen Resonance), or the SeQuent Please DEB (3.0 µg/mm2 paclitaxel; iopromide excipient: B. Braun). Twenty-eight days following balloon deployment, animals underwent repeat angiography for quantitative coronary angiography analysis and euthanasia for histopathologic assessment. By histology, the mean neointimal thickness was 0.44 ± 0.19 mm with PBA, 0.35 ± 0.13 mm with Pantera Lux , 0.61 ± 0.20 mm with Elutax , and 0.47 ± 0.21 mm with SeQuent Please DEB (p=0.02). In comparison with PBA, deployment of the Pantera Lux or the SeQuent Please DEB resulted in delayed healing characterised by significant increases in fibrin, neointimal cell vacuity and delayed re-endothelialisation. In conclusion, investigation of comparative DEB performance in a porcine model of advanced coronary restenosis reveals significant heterogeneity of neointimal suppression between the devices tested with numerically lowest values seen in the Pantera Lux group. On the other hand, evidence of delayed healing was observed in the most effective DEB groups.
Assuntos
Angioplastia com Balão , Reestenose Coronária/terapia , Estenose Coronária/terapia , Vasos Coronários/patologia , Endotélio Vascular/metabolismo , Animais , Reestenose Coronária/etiologia , Reestenose Coronária/patologia , Reestenose Coronária/fisiopatologia , Estenose Coronária/complicações , Estenose Coronária/patologia , Estenose Coronária/fisiopatologia , Vasos Coronários/efeitos dos fármacos , Vasos Coronários/cirurgia , Modelos Animais de Doenças , Stents Farmacológicos/efeitos adversos , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/patologia , Fibrina/metabolismo , Humanos , Neointima , Paclitaxel/administração & dosagem , Suínos , Cicatrização/efeitos dos fármacosRESUMO
The structural characteristics of blood clots are associated with their susceptibility to thrombolysis. As their morphology can be characterized by MRI, several attempts have been made to link the lysability of blood clots with their MRI properties; however, so far no study has associated a clot's lysability with the diffusion properties of the water in the clot. The apparent diffusion coefficient (ADC) is highly sensitive to changes in serum mobility and may be used to distinguish between the non-retracted and the fully retracted regions of the blood clot. Therefore, the ADC may be a suitable, or even a better, marker for an assessment of the clot's retraction and consequently for its lysability than the relaxation time T(2). The purpose of this study was to evaluate whether it is possible to predict the outcome of clot thrombolysis by ADC mapping prior to treatment. After two hours of thrombolysis using a recombinant tissue plasminogen activator in plasma, whole-blood clots were efficiently dissolved in regions with ADC >or= 0.8 x 10(-9) m(2)/s or T(2) >or= 130 ms, whereas dissolution was poor and prolonged in regions with ADC < 0.8 x 10(-9) m(2)/s or T(2) < 130 ms. An analysis based on a comparison between the initial and final ADC and T(2) maps after two hours of thrombolysis showed that the ADC can more accurately detect the different grades of clot retraction than T(2) and predict the regions of a clot that are resistant to thrombolysis. Therefore, the ADC could be used as an efficient prognostic marker for the outcome of thrombolysis. However, in vivo studies are needed to test this idea.
Assuntos
Imageamento por Ressonância Magnética/métodos , Terapia Trombolítica/métodos , Trombose , Fibrina/metabolismo , Humanos , Trombose/metabolismo , Trombose/patologia , Ativador de Plasminogênio Tecidual/metabolismo , Resultado do TratamentoRESUMO
Fibrin represents a suitable target for addressing delivery systems loaded by fibrinolytic drugs. Selective ligands capable to recognize fibrin could be used as targeting moieties for such systems. In this study the interactions between the gamma(312-324) epitope of human fibrin and peptidic ligands were analyzed by using experimental and computational methods. Binding free energies were calculated through the molecular mechanics/generalized born surface area approach. Good qualitative agreements between the experimental and calculated data were obtained. The binding affinity seems to be well correlated (R(2)=0.69) with the changes of the nonpolar solvation energy term computed from solvent-accessible surface area calculation. These results indicate that current methods of estimating binding free energies are efficient for achieving information on protein-ligand interactions.
Assuntos
Fibrina/metabolismo , Peptídeos/metabolismo , Animais , Simulação por Computador , Epitopos , Humanos , Ligantes , Ligação Proteica , Solventes , Ressonância de Plasmônio de Superfície , TermodinâmicaRESUMO
The article contains data on venous thrombosis (VT) recurrence rate in patients with the first episode of thrombus formation after the completion of one-year therapy with warfarin. The investigation included study of the prognostic value of intravascular coagulation marker (thrombus precursor protein --TPP) for the risk of venous retrombosis. The study showed that a high TPP level at the end of standard therapy course with warfarin in patients who had the first episode of spontaneous venous thrombosis is a significant indicator of a possible thrombosis recurrence during the nearest two tears after treatment with anticoagulants.
Assuntos
Anticoagulantes/uso terapêutico , Fibrina/metabolismo , Trombose Venosa/sangue , Varfarina/uso terapêutico , Adulto , Anticoagulantes/administração & dosagem , Biomarcadores/sangue , Ensaio de Imunoadsorção Enzimática , Feminino , Seguimentos , Humanos , Masculino , Prognóstico , Estudos Prospectivos , Fatores de Risco , Prevenção Secundária , Trombose Venosa/tratamento farmacológico , Varfarina/administração & dosagemRESUMO
Formation of fibrin sleeves around catheter tips is a central factor in catheter failure during chronic implantation, and such tissue growth can occur despite administration of anticoagulants. We developed a novel method for monitoring catheter patency. This method recognizes the progressive nature of catheter occlusion, and tracks this process over time through measurement of changes in catheter resistance to a standardized 1 mL bolus infusion from a pressurized reservoir. Two indirect measures of catheter patency were used: (a) reservoir residual pressure and (b) reservoir discharge time. This method was applied to the study of catheter patency in rats comparing the effect of catheter material (silastic, polyurethane, Microrenathanetrade mark), lock solution (heparin, heparin/dexamethasone) and two different cannulation sites (superior vena cava via the external jugular vein, inferior vena cava via the femoral vein). Our findings reveal that application of flexible smaller-size silastic catheters and a dexamethasone lock solution resulted in prolonged catheter patency. Patency could be maintained over nine weeks with the femoral vein catheters, compared with five weeks with the external jugular vein catheters. The current method for measuring catheter patency provides a useful index for the assessment of tissue growth around the catheter tip. The method also provides an objective and quantitative way of comparing changes in catheter patency for different surgical methods and catheter types. Our method improves on the conventional method of assessing catheter occlusion by judging the ability to aspirate from the catheter.